Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.49 |
| ▸ | CCND1 | P24385 | 9/20 | 0.49 |
| ▸ | TDO2 | P48775 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405137 | 0.90 | TDO2 (0.46) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2403897 | 0.90 | HTR2A (0.45) | TDO2MPOHTR2AHCRTR2SLC6A4 | |
| SCHEMBL2406453 | 0.90 | TDO2 (0.47) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2405046 | 0.90 | TDO2 (0.45) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2404622 | 0.88 | TDO2 (0.44) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2410033 | 0.88 | TDO2 (0.44) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2404856 | 0.88 | TDO2 (0.44) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2406526 | 0.88 | TDO2 (0.44) | CDK4CCND1TDO2MPOHTR2A | |
| SCHEMBL2405442 | 0.87 | TDO2 (0.42) | TDO2MPOHTR2AHCRTR2SLC6A4 | |
| SCHEMBL2403964 | 0.84 | HCRTR2 (0.47) | CDK4CCND1TDO2MPOHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CDK4 3031/4885CCND1 3178/4885TDO2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.